CN-122005602-A - Vitamin B12Application of auxiliary therapeutic agent for preventing or treating colorectal cancer precursor lesions

Abstract

The invention belongs to the technical field of biological medicines, and particularly relates to application of vitamin B 12 in preparing an auxiliary therapeutic agent for preventing or treating colorectal cancer pre-lesions. The invention aims to provide a novel preventive intervention means for colorectal cancer (coltis-associated colorectal cancer, CAC) caused by colorectal adenoma canceration process and inflammatory atypical hyperplasia. During colorectal adenoma canceration, vitamin B 12 levels in the circulatory system decrease with progression of the disease. In the mouse model of inflammatory and hereditary colorectal cancer, supplementation with the drug vitamin B 12 can enhance MHC-II signaling and reactivate CD4 effector memory T cell immunity. The invention provides a new idea for further researching an immune recovery strategy and medical application of vitamin B 12 in the colorectal cancer pre-lesion process.

Inventors

• SUN YANG
• ZHOU LISHA
• LIU SHUNJI

Assignees

• 南京大学

Dates

Publication Date

20260512

Application Date

20260330

Claims (7)

1. 1. Use of vitamin B 12 in the manufacture of an adjunctive therapeutic agent for the prevention or treatment of a pre-colorectal cancer lesion.
2. 2. The application of vitamin B 12 in preparing medicine for restoring immunity before colorectal cancer is provided.
3. 3. The use according to claim 2, wherein said restoring pre-colorectal immune function is achieved by restoring immune monitoring function of tertiary lymphoid structures.
4. 4. The use according to claim 3, wherein the immune monitoring function of the tertiary lymphoid structure results in an increased expression of CD74 molecules, enhanced MHC-II signaling, and reactivation of effector memory T cells, restoring an adaptive immune response.
5. 5. The use according to claim 1, wherein vitamin B 12 is at least one active form of methylcobalamin, 5' -deoxyadenosylcobalamin, cyanocobalamin.
6. 6. The use according to claim 1, wherein the adjunctive therapeutic agent is in any one of oral, injectable, and intestinal targeting formulations.
7. 7. The use of claim 4, wherein the reactivating effector memory T cells is achieved by increasing the population of CD4 + effector memory cells and CD127 + KLRG1 - memory-like T cells.

Description

Application of vitamin B 12 in preparing auxiliary therapeutic agent for preventing or treating colorectal cancer precursor lesions Technical Field The invention belongs to the technical field of biological medicines, and particularly relates to application of vitamin B 12 in preparing an auxiliary therapeutic agent for preventing or treating colorectal cancer pre-lesions. Background Colorectal adenomas evolve into high risk for colorectal cancer-early destruction of immune surveillance is a critical event in colorectal tumor evolution and a major obstacle to effective interception of cancer. Although advances in screening and therapy improve prognosis for colorectal cancer patients, most patients are diagnosed after malignant transformation, where the therapeutic response is limited and immune escape has developed. Premalignant lesions, including colorectal adenomas and inflammation-related atypical hyperplasia, are also often detected in other healthy individuals, and therefore, how to rapidly distinguish between a healthy state and a precancerous lesion state, which requires not only early detection, but also mechanical risk stratification to identify lesions that are most likely to progress to malignancy, is a technical challenge in the art. At the same time, it is not clear how the immunological monitoring of the earliest stage of colorectal tumorigenesis is disrupted, and thus there is a lack of therapeutic means for preventing early colorectal cancer canceration. Disclosure of Invention The invention aims to: The invention aims to provide a medicine capable of recovering immune monitoring for colorectal cancer precancerous lesions. Vitamin B 12 shows a decreasing trend in serum of patients with various stages of colorectal cancer precancerous lesions, and vitamin B 12 can effectively inhibit colorectal cancer precancerous lesions. The invention provides a new idea for further researching an immune recovery strategy and medical application of vitamin B 12 in the colorectal cancer pre-lesion process. The invention aims to provide treatment and prevention of vitamin B 12 in colorectal cancer pre-lesions so as to solve the problem of lack of medicaments for immune monitoring recovery treatment in medicaments for treating colorectal cancer in the prior art. Technical proposal Use of vitamin B 12 in the manufacture of an adjunctive therapeutic agent for the prevention or treatment of a pre-colorectal cancer lesion. The application of vitamin B 12 in preparing medicine for restoring immunity before colorectal cancer is provided. The use, wherein said restoring pre-colorectal immune function is achieved by restoring immune monitoring function of tertiary lymphoid structures. The use is characterized in that the immune monitoring function of the tertiary lymphoid structure results in an increase in the expression level of CD74 molecules, enhances MHC-II signaling, and re-activates effector memory T cells, restoring an adaptive immune response. The use, wherein vitamin B 12 is at least one active form of methylcobalamin, 5' -deoxyadenosylcobalamin, cyanocobalamin. The application is characterized in that the auxiliary therapeutic agent is any one of an oral preparation, an injection preparation and an intestinal targeting preparation. The use, wherein said reactivating effector memory T cells is achieved by adding CD4 + effector memory cells and CD127 +KLRG1- memory-like T cell populations. For treating colorectal adenoma, vitamin B 12 can be used as adjuvant therapy for patients with high risk of colorectal adenoma, and can restore immunity and reduce cancer risk. For treating inflammation-related atypical hyperplasia, vitamin B 12 can be supplemented to restore immunity monitoring function, inhibit inflammation progress, and slow down canceration process for patients with inflammation atypical hyperplasia. Monitoring and assessment vitamin B 12 levels in the patient's serum, immune function (e.g., activation of CD4 positive T cells, activation of MHC-II signaling), and colonoscopy results are periodically monitored during treatment to assess the efficacy and safety of vitamin B 12 treatment. Advantageous effects Vitamin B 12 is a water-soluble vitamin that is involved in DNA synthesis, cell division and methylation reactions and plays a key role in maintaining genomic stability and regulating homocysteine metabolism. Since the occurrence of colorectal cancer precancerous lesions is closely related to DNA damage, abnormal methylation and chronic inflammation, vitamin B 12 has not been reported to restore precancerous immune function by improving DNA repair, maintaining normal methylation levels and reducing oxidative stress. The invention discovers and verifies that the serum concentration of vitamin B 12 in each stage of precancerous lesions of colorectal cancer is reduced through clinical samples and animal model analysis, and the immune monitoring function of an immune structure-tertiary lymphoid structure